The Cardiovascular Market Outlook to 2014: Competitive landscape, global market analysis and pipeline analysis

NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Cardiovascular Market Outlook to 2014: Competitive landscape, global market analysis and pipeline analysis

http://www.reportlinker.com/p0185306/The-Cardiovascular-Market-Outlook-to-Competitive-landscape-global-market-analysis-and-pipeline-analysis.html?d=CPDAIN5

The Cardiovascular Market Outlook to 2014 provides comprehensive coverage of the cardiovascular market, incorporating a disease overview and detailed epidemiological analyses of the major indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands within each indication, in order to enable the reader to identify growth brands, key drug classes and leading players through 2014.

The cardiovascular market may be segmented into numerous subcategories, including antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents. While established treatments are currently available for each of these therapeutic subcategories, these markets are large and significant unmet medical needs still exists. Among the various cardiovascular indications, dyslipidemia had the highest prevalence in 2008, with over 300m people affected by the condition.

The global cardiovascular market is quite dynamic and has remained a leading therapy area in the global pharmaceutical market. Although the seven major markets (7MM) have captured a significant market share of the global cardiovascular market sales, these countries have recorded a strong Y-o-Y decline in 2008. The US continued to be a dominant market but registered a Y-o-Y decline in 2008, which was mainly attributed to increasing generic presence and market maturity in several key therapeutic categories.

Key features of this report

• Epidemiological analysis and forecast prevalence of the major cardiovascular indications such as hypertension, dyslipidemia and stroke over the period 2008–14.

• Forecasts and analysis of the major products in the cardiovascular market over the period 2008-14 spread across the major indications and classes of treatments.

• Overview of key events in the global cardiovascular market that have impacted treatment trends and sales potential across the major cardiovascular indications.

• Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.

Scope of this report

• Quantify patient potential, assess treatment trends and sales patterns across the major cardiovascular disorder indications in the US, Japan and top 5 EU markets.

• Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of the major classes such as antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents.

• Compare the franchises of top pharmaceutical marketers across major indications, and evaluate how market share of leading companies, such as Pfizer, Sanofi-Aventis, Novartis, Merck, BMS and AstraZeneca will change over the next 5 years.

• Quick and comprehensive understanding of how recent events are affecting the performance of major products, and how leading players are confronting competitive challenges in the cardiovascular marketplace.

Key questions answered

• What will be the major growth indications and the accompanying growth drivers in the cardiovascular arena over the period 2008–14?

• What are the current trends within the major therapy areas such as antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents across the seven major markets?

• How have recent launches from companies such as Pfizer, Sanofi-Aventis, Novartis, Merck, BMS and AstraZeneca performed in the market place?

• What are the most promising compounds currently in clinical development for major cardiovascular indications, and what is the forecast commercial potential of these products through 2014?

Companies mentioned

AstraZeneca , Bristol-Myers Squibb (BMS) , Merck & Co. , Novartis , Pfizer , Sanofi-Aventis

Table of Contents

The Cardiovascular Market Outlook to 2014

Executive summary 12

Overview and epidemiology of cardiovascular disorders 12

Global market analysis 12

Pipeline analysis 13

Competitive landscape 14

Scope and methodology 16

Scope 16

Methodology 17

Chapter 1 Overview and epidemiology of cardiovascular disorders 20

Summary 20

Introduction 20

Predisposing factors 21

Risk factors 24

Hypertension 24

Diagnosis, treatment and management 25

Epidemiology 27

Forecast epidemiology 28

Dyslipidemia 29

Diagnosis, treatment and management 30

Epidemiology 33

Forecast epidemiology 34

Cardiovascular diseases 35

Arteriosclerosis/atherosclerosis 35

Thrombosis 35

Cardiac arrhythmias 35

Myocardial infarction (MI) 36

Acute coronary syndrome (ACS) 36

Congestive heart failure (CHF) 36

Coronary artery disease (CAD) 36

Peripheral artery disease (PAD) 36

Pulmonary hypertension 36

Angina pectoris 37

Stroke 37

Epidemiology 38

Forecast epidemiology 39

Chapter 2 Global market analysis 42

Summary 42

Introduction 43

Market analysis by country 44

Key events in the cardiovascular market 48

Wider indications for Crestor 48

Evolving dynamics of the cholesterol market – patent expirations but an increasing patient base 49

Heightened interest in the HDL cholesterol market 49

ARBs a growing hypertension drug class 49

Tekturna/Rasilez uptake slower than expected 50

Micardis label expansion in the EU 50

Market analysis by drug class 51

Antihypertensive treatments 52

Introduction 52

Different classes of antihypertensives 53

Leading treatment brands by drug class 54

Key brands analysis 56

Diovan/Co-Diovan 56

Norvasc 57

Cozaar 58

Trends in generics usage 59

Antidyslipidemics 60

Introduction 60

Antidyslipidemics drug classes 61

Leading treatment brands by drug class 62

Key brands analysis 64

Lipitor 64

Crestor 66

Trends in generics usage 70

Antithrombotics treatments 71

Introduction 71

Antithrombotics drug classes 72

Leading treatment brands by drug class 73

Key brands analysis 74

Plavix 74

Lovenox 77

Trends in generics usage 78

Other cardiovascular agents 79

Introduction 79

Leading brands by drug class 79

Key brands analysis 80

Tracleer 80

Trends in generics usage 82

Cardiac therapies 82

Introduction 82

Market analysis by drug class 83

Leading treatment brands by drug class 84

Trends in generics usage 85

Cardiovascular sales forecast to 2014 86

Leading brands dynamics 87

Chapter 3 Pipeline analysis 90

Summary 90

Introduction 91

Key events in the cardiovascular market 91

BMS/Pfizer's apixaban is on track for EU regulatory submission in venous

thromboembolism (VTE) 91

Plavix receives a US warning on omeprazole interaction 91

Mipomersen from Genzyme may become a novel option for high cholesterol 92

New treatments drive robust growth of the anticoagulants class 92

Persistent interest in drugs which increase HDL cholesterol levels 93

Valturna remains the first hypertension combination drug to receive US approval 94

NICE drafts guidelines on hypertension treatment in pregnancy 95

Cardiovascular pipeline 96

Leading drugs in development 98

Profiles of key pipeline products 99

Recently approved/launched drugs 99

Pradaxa/Rendix (dabigatran) – Boehringer Ingelheim 99

Multaq (dronedarone) – Sanofi-Aventis 100

Xarelto (rivaroxaban) – Bayer Schering/J&J 102

Effient/Efient (prasugrel) – Eli Lilly/Daiichi Sankyo 104

Recently filed/pre-registration compounds 106

Apixaban – Bristol-Myers Squibb (BMS)/Pfizer 106

Certriad (rosuvastatin/ fenofibric acid) – AstraZeneca/Abbott 107

Brilinta (ticagrelor/AZD6140) – AstraZeneca 108

Phase II/III compounds 110

LCZ696 – Novartis 110

SCH 530348 – Merck 111

Edoxaban (DU-176b) – Daiichi Sankyo 113

Tyrisa/darapladib – GSK 114

Betrixaban – Portola/Merck 115

Pipeline forecast 117

Chapter 4 Competitive landscape 120

Summary 120

Introduction 121

Competitive positioning of top players in the cardiovascular market 121

Detailed analysis of leading cardiovascular players 123

Pfizer 123

Overview 123

Regional sales distribution 124

Sales focus by drug class 124

Marketed product portfolio 126

R&D pipeline analysis 128

Strategic and growth analysis 129

Sanofi-Aventis 131

Overview 131

Regional sales distribution 131

Sales focus by drug class 132

Marketed product portfolio 135

R&D pipeline analysis 137

Strategic and growth analysis 138

Novartis 139

Overview 139

Regional sales distribution 140

Sales focus by drug class 140

Marketed product portfolio 142

R&D pipeline analysis 144

Strategic and growth analysis 145

Merck & Co 146

Overview 146

Regional sales distribution 147

Sales focus by drug class 148

Marketed product portfolio 150

R&D pipeline analysis 151

Strategic and growth analysis 153

Bristol-Myers Squibb (BMS) 154

Overview 154

Regional sales distribution 155

Sales focus by drug class 155

Marketed product portfolio 156

R&D pipeline analysis 158

Strategic and growth analysis 159

AstraZeneca 161

Overview 161

Regional sales distribution 161

Sales focus by drug class 162

Marketed product portfolio 163

R&D pipeline analysis 166

Strategic and growth analysis 167

Competitive positioning of top generic players in the cardiovascular market 168

Leading generic players by region 171

Appendix 173

IMS Data 173

Glossary 175

Index 179

List of Figures

Figure 1.1: Cardiovascular disease etiology 23

Figure 1.2: Cardiovascular risk factors 24

Figure 1.3: Definition and classification of hypertension 25

Figure 1.4: Hypertension - treatment options 26

Figure 1.5: Types of lipoproteins 30

Figure 1.6: Interpretation of blood lipid levels 31

Figure 1.7: LDL levels and therapy patterns 32

Figure 2.8: Relative positions of the 7MM in the global cardiovascular market, 2008 44

Figure 3.9: Cardiovascular pipeline by indication and stage of development, 2009 96

Figure 3.10: Leading recently marketed and late-stage R&D products in the cardiovascular market, 2009 98

Figure 4.11: Competitive dynamics of the top 10 cardiovascular players over the period 2007–08 122

Figure 4.12: Pfizer's top 10 cardiovascular drug classes by sales ($m), 2008 125

Figure 4.13: Sanofi-Aventis' top 10 cardiovascular drug classes by sales ($m), 2008 133

Figure 4.14: Novartis' top 10 cardiovascular drug classes by sales ($m), 2008 141

Figure 4.15: Merck's top 10 cardiovascular drug classes by sales ($m), 2008 148

Figure 4.16: BMS' top 10 cardiovascular drug classes by sales ($m), 2008 156

Figure 4.17: AstraZeneca's top 10 cardiovascular drug classes by sales ($m), 2008 163

Figure 4.18: Competitive positioning of the top 10 generic players in the global cardiovascular market, 2008 169

Figure 4.19: Relative positioning of the top 10 generic and branded players in the global cardiovascular market, 2008 171

List of Tables

Table 1.1: Estimated prevalence of cardiovascular disorders across seven major markets (in thousands), 2008 21

Table 1.2: Estimated prevalence of hypertension across the seven major markets (in thousands), 2008 27

Table 1.3: Forecast epidemiology of hypertension across the seven major markets (in thousands), 2008–14 28

Table 1.4: Estimated prevalence of dyslipidemia across the seven major markets (in thousands), 2008 33

Table 1.5: Forecast epidemiology of dyslipidemia across the seven major markets (in thousands), 2008–14 34

Table 1.6: Estimated prevalence of stroke across the seven major markets (in thousands), 2008 38

Table 1.7: Forecast epidemiology of stroke across the seven major markets (in thousands), 2008– 14 39

Table 2.8: US cardiovascular drug sales by ATC3 class, 2008 US$ millions 45

Table 2.9: Japan cardiovascular drug sales by ATC3 class, 2008 US$ millions 45

Table 2.10: France cardiovascular drug sales by ATC3 class, 2008 US$ millions 46

Table 2.11: Germany cardiovascular drug sales by ATC3 class, 2008 US$ millions 46

Table 2.12: Italy cardiovascular drug sales by ATC3 class, 2008 US$ millions 47

Table 2.13: Spain cardiovascular drug sales by ATC3 class, 2008 US$ millions 47

Table 2.14: UK cardiovascular drug sales by ATC3 class, 2008 US$ millions 48

Table 2.15: The global cardiovascular market by therapeutic segments ($m), 2007–2008 51

Table 2.16: Leading antihypertensive brands in the global cardiovascular market, 2008 55

Table 2.17: Comparison of generics and branded drugs in the global antihypertensive market, 2008 60

Table 2.18: Leading antidyslipidemic treatments in the global cardiovascular market, 2008 63

Table 2.19: Comparison of generics and branded drugs in the global antidyslipidemic market, 2008 71

Table 2.20: Leading antithrombotics treatments in the global cardiovascular market, 2008 74

Table 2.21: Comparison of generics and branded drugs in the global antithrombotics market, 2008 79

Table 2.22: Other cardiovascular treatments in the global cardiovascular market 2008 80

Table 2.23: Comparison of generics and branded drugs in the other cardiovascular agents market, 2008 82

Table 2.24: Leading cardiac therapies in the global cardiovascular market 2008 84

Table 2.25: Comparison of generics and branded drugs in the global cardiac therapies market, 2008 85

Table 2.26: Cardiovascular market sales forecast by therapeutic segments ($m), 2008–14 86

Table 2.27: Leading brands in the global cardiovascular market ($m), 2008 87

Table 2.28: Top 10 brands of the cardiovascular market, sales forecast 2008–14 88

Table 3.29: An overview of Pradaxa 99

Table 3.30: An overview of Multaq 101

Table 3.31: An overview of Xarelto 103

Table 3.32: An overview of Effient 105

Table 3.33: An overview of apixaban 106

Table 3.34: An overview of Certriad 108

Table 3.35: An overview of Brilinta 109

Table 3.36: An overview of LCZ696 110

Table 3.37: An overview of SCH530348 111

Table 3.38: An overview of edoxaban (DU-176b) 113

Table 3.39: An overview of Tyrisa 114

Table 3.40: An overview of betrixaban 116

Table 3.41: Key pipeline and recently approved/launched cardiovascular products sales forecast, 2008–14 118

Table 4.42: Leading players of the cardiovascular market based on prescription sales, 2008 123

Table 4.43: Regional sales distribution of Pfizer, 2008 124

Table 4.44: Pfizer's leading cardiovascular brands, 2008 126

Table 4.45: Pfizer's cardiovascular R&D portfolio, 2009 129

Table 4.46: Regional sales distribution of Sanofi-Aventis, 2008 132

Table 4.47: Sanofi-Aventis' leading cardiovascular brands, 2008 135

Table 4.48: Sanofi-Aventis' cardiovascular R&D portfolio, 2009 137

Table 4.49: Regional sales distribution of Novartis, 2008 140

Table 4.50: Novartis' leading cardiovascular brands, 2008 142

Table 4.51: Novartis' cardiovascular R&D portfolio, 2009 145

Table 4.52: Regional sales distribution of Merck, 2008 147

Table 4.53: Merck's leading cardiovascular brands, 2008 150

Table 4.54: Merck's cardiovascular R&D portfolio, 2009 152

Table 4.55: Regional sales distribution of BMS, 2008 155

Table 4.56: BMS' leading cardiovascular brands, 2008 157

Table 4.57: BMS' cardiovascular R&D portfolio, 2009 159

Table 4.58: Regional sales distribution of AstraZeneca, 2008 162

Table 4.59: AstraZeneca's leading cardiovascular brands, 2008 164

Table 4.60: AstraZeneca's cardiovascular R&D portfolio, 2009 166

Table 4.61: Leading generic players in global cardiovascular market, 2008 170

Table 4.62: Leading generic players by region, 2008 172

To order this report:

Cardiovascular Devices Industry: The Cardiovascular Market Outlook to 2014: Competitive landscape, global market analysis and pipeline analysis

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker